The new product is a fixed-dose combination (in both oral and IV forms) containing netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron.
The agreement allows Helsinn to take care of all development activities (CMC, preclinical and clinical), obtaining regulatory approvals, and holding the New Drug Application.
Additionally, Helsinn will also be responsible for the supply of the product for commercial use in Germany.